JPMorgan Boosts Target on Human Genome (HGSI) to $35
HGSI Hot Sheet
Rating Summary:7 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Following yesterday's news that BENLYSTA met its primary endpoint in a second Phase 3 trial, and the resulting 35% spike in the stock, JPMorgan has raised its price target on shares of Human Genome Sciences (Nasdaq: HGSI) from $25 to $35. The firm maintains its Overweight rating.
The stock is continuing higher today, currently up about 1% to $25.53. JPMorgan's new price target represents potential upside of about 37%.
To see all the analyst calls on shares of Human Genome, including a price target raise at Goldman, visit our Analyst Ratings page.
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States.
The stock is continuing higher today, currently up about 1% to $25.53. JPMorgan's new price target represents potential upside of about 37%.
To see all the analyst calls on shares of Human Genome, including a price target raise at Goldman, visit our Analyst Ratings page.
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States.
You May Also Be Interested In
- Nomura Securities Maintains a 'Neutral' on Tiffany & Co. (TIF); Cutting Estimates and Price Target
- Needham & Company Maintains a 'Hold' on Teva Pharma (TEVA); Adjusting Estimates
- Needham & Company Reiterates a 'Buy' on UQM Technologies (UQM); Increasing EV Adoption
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
